<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33630801</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-0229</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical nuclear medicine</Title>
          <ISOAbbreviation>Clin Nucl Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis.</ArticleTitle>
        <Pagination>
          <StartPage>e327</StartPage>
          <EndPage>e328</EndPage>
          <MedlinePgn>e327-e328</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/RLU.0000000000003547</ELocationID>
        <Abstract>
          <AbstractText>In paraneoplastic cerebellar degeneration (PCD), the standard diagnostic workup might be inconclusive, especially in seronegative subtypes. Brain 18F-FDG PET is an accurate supportive diagnostic tool in immune-mediated disorders, but findings in PCD are controversial. Semiquantitative analysis of 18F-FDG PET can meaningfully assist visual assessment in different neurological conditions and has been mainly applied to disclose regional hypometabolism. We describe a seronegative PCD associated with small cell lung cancer in which 18F-FDG PET semiquantitative analysis accurately disclosed the longitudinal pathological changes of brain metabolism occurring in the acute and posttreatment remission stages and paralleling clinical impairment and response to treatment.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Massa</LastName>
            <ForeName>Federico</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Filippi</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benedetti</LastName>
            <ForeName>Luana</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morbelli</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Science, University of Genoa, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nobili</LastName>
            <ForeName>Flavio</ForeName>
            <Initials>F</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Nucl Med</MedlineTA>
        <NlmUniqueID>7611109</NlmUniqueID>
        <ISSNLinking>0363-9762</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0Z5B2CJX4D</RegistryNumber>
          <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="N">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055752" MajorTopicYN="N">Small Cell Lung Carcinoma</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflicts of interest and sources of funding: S.M. has received speaker honoraria from GE Healthcare. F.N. has received fees for participating in boards from Roche, and speaker honoraria from Bial e G.E. Healthcare. The other authors have nothing to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33630801</ArticleId>
        <ArticleId IdType="doi">10.1097/RLU.0000000000003547</ArticleId>
        <ArticleId IdType="pii">00003072-202106000-00031</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140.</Citation>
        </Reference>
        <Reference>
          <Citation>Cistaro A, Valentini MC, Chiò A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39:251–259.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmahmann JD. The cerebellum and cognition. Neurosci Lett. 2019;688:62–75.</Citation>
        </Reference>
        <Reference>
          <Citation>Lv RJ, Pan J, Zhou G, et al. Semi-quantitative FDG-PET analysis increases the sensitivity compared with visual analysis in the diagnosis of autoimmune encephalitis. Front Neurol. 2019;10:576.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117:859–876.</Citation>
        </Reference>
        <Reference>
          <Citation>Wolff M, Vann SD. The cognitive thalamus as a gateway to mental representations. J Neurosci. 2019;39:3–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J, Wang W, Zhao Y, et al. Cerebellar hypermetabolism in a case of paraneoplastic cerebellar syndrome with the primary lymphoepithelial carcinoma in tonsil. Clin Nucl Med. 2019;44:812–814.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharma P, Mazumdar B, Chatterjee P. Cerebellar hypermetabolism on 18F-FDG PET/CT with normal MRI in a case of paraneoplastic cerebellar degeneration with negative antibodies. Rev Esp Med Nucl Imagen Mol. 2015;34:79–80.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdulaziz ATA, Yu XQ, Zhang L, et al. Paraneoplastic cerebellar degeneration associated with cerebellar hypermetabolism: case report. Medicine (Baltimore). 2018;97:e10717.</Citation>
        </Reference>
        <Reference>
          <Citation>Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry. 2006;77:525–528.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33630801</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-0229</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical nuclear medicine</Title>
          <ISOAbbreviation>Clin Nucl Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis.</ArticleTitle>
        <Pagination>
          <StartPage>e327</StartPage>
          <EndPage>e328</EndPage>
          <MedlinePgn>e327-e328</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/RLU.0000000000003547</ELocationID>
        <Abstract>
          <AbstractText>In paraneoplastic cerebellar degeneration (PCD), the standard diagnostic workup might be inconclusive, especially in seronegative subtypes. Brain 18F-FDG PET is an accurate supportive diagnostic tool in immune-mediated disorders, but findings in PCD are controversial. Semiquantitative analysis of 18F-FDG PET can meaningfully assist visual assessment in different neurological conditions and has been mainly applied to disclose regional hypometabolism. We describe a seronegative PCD associated with small cell lung cancer in which 18F-FDG PET semiquantitative analysis accurately disclosed the longitudinal pathological changes of brain metabolism occurring in the acute and posttreatment remission stages and paralleling clinical impairment and response to treatment.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Massa</LastName>
            <ForeName>Federico</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Filippi</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benedetti</LastName>
            <ForeName>Luana</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morbelli</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Science, University of Genoa, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nobili</LastName>
            <ForeName>Flavio</ForeName>
            <Initials>F</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Nucl Med</MedlineTA>
        <NlmUniqueID>7611109</NlmUniqueID>
        <ISSNLinking>0363-9762</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0Z5B2CJX4D</RegistryNumber>
          <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="N">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055752" MajorTopicYN="N">Small Cell Lung Carcinoma</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflicts of interest and sources of funding: S.M. has received speaker honoraria from GE Healthcare. F.N. has received fees for participating in boards from Roche, and speaker honoraria from Bial e G.E. Healthcare. The other authors have nothing to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33630801</ArticleId>
        <ArticleId IdType="doi">10.1097/RLU.0000000000003547</ArticleId>
        <ArticleId IdType="pii">00003072-202106000-00031</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140.</Citation>
        </Reference>
        <Reference>
          <Citation>Cistaro A, Valentini MC, Chiò A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39:251–259.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmahmann JD. The cerebellum and cognition. Neurosci Lett. 2019;688:62–75.</Citation>
        </Reference>
        <Reference>
          <Citation>Lv RJ, Pan J, Zhou G, et al. Semi-quantitative FDG-PET analysis increases the sensitivity compared with visual analysis in the diagnosis of autoimmune encephalitis. Front Neurol. 2019;10:576.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117:859–876.</Citation>
        </Reference>
        <Reference>
          <Citation>Wolff M, Vann SD. The cognitive thalamus as a gateway to mental representations. J Neurosci. 2019;39:3–14.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J, Wang W, Zhao Y, et al. Cerebellar hypermetabolism in a case of paraneoplastic cerebellar syndrome with the primary lymphoepithelial carcinoma in tonsil. Clin Nucl Med. 2019;44:812–814.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharma P, Mazumdar B, Chatterjee P. Cerebellar hypermetabolism on 18F-FDG PET/CT with normal MRI in a case of paraneoplastic cerebellar degeneration with negative antibodies. Rev Esp Med Nucl Imagen Mol. 2015;34:79–80.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdulaziz ATA, Yu XQ, Zhang L, et al. Paraneoplastic cerebellar degeneration associated with cerebellar hypermetabolism: case report. Medicine (Baltimore). 2018;97:e10717.</Citation>
        </Reference>
        <Reference>
          <Citation>Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry. 2006;77:525–528.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
